Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine
Arthritis & Rheumatology · 14.05.2026
DOI: 10.1002/art.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 14.05.2026. Verfasst von Reem Farhat und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes for Health Research (CIHR), Canadian Initiative for Outcomes in Rheumatology cAre (CIORA), Canadian Institutes of Health Research.
Abstract (Originalsprache)
Objective
To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort.
Methods
LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru, and Mexico. Pregnant women with SLE are enrolled before 17 weeks and followed in the second (20–24 weeks) and third (30–34 weeks) trimesters and postpartum (8–12 weeks). Because ICP occurs after 20 weeks, only pregnancies with a second‐trimester visit were included. Follow‐up began at that visit and continued until delivery. AZA exposure was modeled as time varying. The primary outcome was iatrogenic delivery for ICP or spontaneous preterm birth occurring after ICP diagnosis. Multivariable Cox models with frailties adjusted for relevant covariates. At the Montreal site, thiopurine metabolites and shunting were assessed.
Results
Among 127 SLE pregnancies (46 AZA exposed, 81 unexposed), 10 ICP cases occurred (each in a distinct woman): 8 among AZA exposed (17.4%, 95% confidence interval [CI] 9.1–30.7) and 2 among unexposed (2.5%, 95% CI 0.7–8.6). AZA exposure was associated with a substantially increased risk of ICP (adjusted hazard ratio 12.1, 95% CI 2.4–59.7). All ICP cases with metabolite data (4 of 4) showed second‐trimester shunting. Among all pregnancies with second‐trimester metabolite data (n = 22), 36.4% (95% CI 19.7–57.0) were shunting, and 50.0% (95% CI 21.5–78.5) of these developed ICP.
Conclusion
We observed that AZA exposure may be strongly associated with ICP in SLE pregnancies. Second‐trimester thiopurine shunting may identify women at high risk, supporting the value of metabolite monitoring.
Autor:innen und Institutionen
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Medicine, Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Critical Care Medicine, Division of Rheumatology, Instituto Nacional de Perinatologia Isidro Espinosa De Los Reyes, Mexico City, Mexico.
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.
- Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Centre ARThrite, CHU de Québec, Université Laval, Quebec City, Quebec, Canada.
ORCID-Profile: Reem Farhat, Sang-Cheol Bae, Megan R W Barber, Ann E Clarke, Paul R Fortin, Zahi Touma, Carl A Laskin, Manuel F Ugarte-Gil, Alexandra Legge, Sasha Bernatsky, Évelyne Vinet
Förderung
- Canadian Institutes for Health Research (CIHR)
- Canadian Initiative for Outcomes in Rheumatology cAre (CIORA)
- Canadian Institutes of Health Research
Zitieren
APA
Farhat, R., Zamora-Medina, M. D. C., Bae, S. C., Barber, M. R. W., Clarke, A. E., Fortin, P. R., Touma, Z., Laskin, C. A., Malhamé, I., Sebastiani, G., Peschken, C., Ugarte-Gil, M. F., Legge, A., Bernatsky, S., & Vinet, É. (2026). Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine. Arthritis & Rheumatology. https://doi.org/10.1002/art.70208
Vancouver
Farhat R, Zamora-Medina MDC, Bae SC, Barber MRW, Clarke AE, Fortin PR, et al. Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine. Arthritis & Rheumatology. 2026. doi:10.1002/art.70208
BibTeX
@article{Farhat2026,
author = {Farhat, Reem and Zamora-Medina, Maria Del Carmen and Bae, Sang-Cheol and Barber, Megan R W and Clarke, Ann E and Fortin, Paul R and Touma, Zahi and Laskin, Carl A and Malhamé, Isabelle and Sebastiani, Giada and Peschken, Christine and Ugarte-Gil, Manuel F and Legge, Alexandra and Bernatsky, Sasha and Vinet, Évelyne},
title = {Increased Risk of Intrahepatic Cholestasis of Pregnancy in Women With Systemic Lupus Erythematosus Exposed to Azathioprine},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70208}
}
EUVIMED